The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Untangling the ErbB signalling network

2001 • 6,623 citations

Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery

1997 • 5,665 citations

PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

1997 • 4,753 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis

1995 • 4,003 citations

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

2004 • 3,304 citations

Epidermal growth factor-related peptides and their receptors in human malignancies

1995 • 2,689 citations

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

2004 • 2,674 citations

Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL

1996 • 2,627 citations

NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

2000 • 2,394 citations

Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death

1995 • 2,114 citations

Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms

1999 • 1,897 citations

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 • 1,510 citations

The EGF receptor family as targets for cancer therapy

2000 • 1,339 citations

The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy

1999 • 840 citations

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 • 828 citations

Mechanism of activation and function of protein kinase B

1998 • 753 citations

Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin

2000 • 748 citations

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

2000 • 667 citations

14-3-3 Proteins and Survival Kinases Cooperate to Inactivate BAD by BH3 Domain Phosphorylation

2000 • 634 citations

The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling

1997 • 591 citations

Regulation of G₁progression by thePTENtumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway

1999 • 572 citations

In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

2004 • 544 citations

ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.

1994 • 520 citations

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

2001 • 516 citations

Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma

2004 • 470 citations

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

2003 • 457 citations

Epidermal growth factor receptor inhibition strategies in oncology

2004 • 413 citations

Regulation of Bad Phosphorylation and Association with Bcl-xL by the MAPK/Erk Kinase

1999 • 385 citations

Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor

1998 • 304 citations

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

2001 • 299 citations

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

2003 • 284 citations

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2

2002 • 269 citations

Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway

1999 • 258 citations

Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification.

1994 • 255 citations

Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.

2000 • 245 citations

Controlling Epidermal Growth Factor (EGF)-stimulated Ras Activation in Intact Cells by a Cell-permeable Peptide Mimicking Phosphorylated EGF Receptor

1996 • 238 citations

Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor

2002 • 208 citations

The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.

2002 • 208 citations

ErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor

1994 • 194 citations

Growth stimulation by coexpression of transforming growth factor-alpha and epidermal growth factor-receptor in normal and adenomatous human colon epithelium.

1990 • 149 citations

Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.

2000 • 126 citations

Estradiol Abrogates Apoptosis in Breast Cancer Cells through Inactivation of BAD: Ras-dependent Nongenomic Pathways Requiring Signaling through ERK and Akt

2004 • 124 citations

14-3-3 Proteins and Survival Kinases Cooperate to Inactivate BAD by BH3 Domain Phosphorylation

2000 • 123 citations

Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of MalignantversusNormal Prostate Epithelial Cells

2004 • 119 citations

MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors

2004 • 112 citations

Flow cytometric analysis of G₁‐ and G₂/M‐phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements

1990 • 92 citations

Topical Treatment with Inhibitors of the Phosphatidylinositol 3′-Kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient Mice

2004 • 75 citations

A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene.

1994 • 65 citations

Evidence That Phosphatidylinositol 3-Kinase- and Mitogen-activated Protein Kinase Kinase-4/c-Jun NH2-terminal Kinase-dependent Pathways Cooperate to Maintain Lung Cancer Cell Survival

2003 • 59 citations

Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved

2003 • 57 citations

EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells

1999 • 44 citations

Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells

2001 • 28 citations

Heregulin-? is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells

2000 • 23 citations